Achieve Life Sciences Inc (SP4P) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Achieve Life Sciences Inc (SP4P) has a cash flow conversion efficiency ratio of -0.835x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.98 Million ≈ $-21.02 Million USD) by net assets (€21.52 Million ≈ $25.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SP4P net asset quality index to measure how much of total assets are equity-financed.
Achieve Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Achieve Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Achieve Life Sciences Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Achieve Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Achieve Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DONGGUAN R.COMMERC. H YC1
F:857
|
N/A |
|
Everbright Jiabao Co Ltd
SHG:600622
|
0.042x |
|
Jiangxi Naipu Mining Machinery
SHE:300818
|
-0.022x |
|
SKS Technologies Group Ltd
AU:SKS
|
0.652x |
|
Tengda Construction Group Co Ltd
SHG:600512
|
-0.002x |
|
MN Holdings Berhad
KLSE:0245
|
0.245x |
|
Bewi Asa
OL:BEWI
|
0.034x |
|
Shoppers Stop Limited
NSE:SHOPERSTOP
|
1.280x |
Annual Cash Flow Conversion Efficiency for Achieve Life Sciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Achieve Life Sciences Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Achieve Life Sciences Inc (SP4P) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €21.52 Million ≈ $25.16 Million |
€-49.47 Million ≈ $-57.83 Million |
-2.299x | -61.38% |
| 2024-12-31 | €20.90 Million ≈ $24.43 Million |
€-29.77 Million ≈ $-34.80 Million |
-1.424x | -108.43% |
| 2023-12-31 | €-1.45 Million ≈ $-1.69 Million |
€-24.48 Million ≈ $-28.62 Million |
16.905x | +473.82% |
| 2022-12-31 | €8.30 Million ≈ $9.71 Million |
€-37.55 Million ≈ $-43.90 Million |
-4.522x | -330.76% |
| 2021-12-31 | €28.04 Million ≈ $32.78 Million |
€-29.44 Million ≈ $-34.42 Million |
-1.050x | -190.52% |
| 2020-12-31 | €37.29 Million ≈ $43.59 Million |
€-13.47 Million ≈ $-15.75 Million |
-0.361x | +57.13% |
| 2019-12-31 | €18.05 Million ≈ $21.10 Million |
€-15.22 Million ≈ $-17.79 Million |
-0.843x | -25.40% |
| 2018-12-31 | €15.80 Million ≈ $18.47 Million |
€-10.62 Million ≈ $-12.42 Million |
-0.672x | +41.84% |
| 2017-12-31 | €7.88 Million ≈ $9.21 Million |
€-9.11 Million ≈ $-10.65 Million |
-1.156x | -10752.47% |
| 2016-12-31 | €18.97 Million ≈ $22.17 Million |
€-202.00K ≈ $-236.16K |
-0.011x | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more